Is LOBEF or MRK a better dividend investment in 2026?

LOBEF currently yields 3861.00% with a 5% 5-year dividend growth rate. MRK yields 2.76% with 8.2% growth. The better choice depends on your goal: LOBEF offers higher current income.

What is the dividend yield difference between LOBEF and MRK?

LOBEF has a forward dividend yield of 3861.00% ($2.00/share annually). MRK yields 2.76% ($3.32/share annually). The yield gap is 3858.24 percentage points.

Home › Compare › LOBEF vs MRK

LOBEF vs MRK: Dividend Comparison 2026

LOBEF yields 3861.00% · MRK yields 2.76%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 LOBEF wins by $5102776617539.95M in total portfolio value

INVESTMENT

TIME HORIZON10 years

LOBEF

● Live price

3861.00%

Share price

$0.05

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$5102776617540.00M

Annual income

$4,855,397,881,919,778,000.00

Full LOBEF calculator →

MRK

Merck & Co. Inc.

● Live price

2.76%

Share price

$120.31

Annual div

$3.32

5Y div CAGR

32.7%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$56.8K

Annual income

$9,798.13

Full MRK calculator →

Portfolio growth — LOBEF vs MRK

📍 LOBEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	LOBEF	MRK
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, LOBEF + MRK cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

LOBEF pays

MRK pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LOBEF

Annual income on $10K today (after 15% tax)

$328,185.33/yr

After 10yr DRIP, annual income (after tax)

$4,127,088,199,631,811,000.00/yr

MRK

Annual income on $10K today (after 15% tax)

$234.56/yr

After 10yr DRIP, annual income (after tax)

$8,328.41/yr

At 15% tax rate, LOBEF beats the other by $4,127,088,199,631,803,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LOBEF + MRK for your $10,000?

LOBEF: 50%MRK: 50%

100% MRK50/50100% LOBEF

Portfolio after 10yr

$2551388308770.03M

Annual income

$2,427,698,940,959,894,000.00/yr

Blended yield

95.15%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

LOBEF

No analyst data

Altman Z

-9.3

Piotroski

3/9

MRK

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$128.54

+6.8% upside vs current

Range: $100.00 — $150.00

Altman Z

4.0

Piotroski

6/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LOBEF buys

MRK buys

No recent congressional trades found for LOBEF or MRK in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricLOBEFMRK

Forward yield	3861.00% ✓	2.76%
Annual dividend / share	$2.00	$3.32 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	32.7% ✓
Portfolio after 10y	$5102776617540.00M ✓	$56.8K
Annual income after 10y	$4,855,397,881,919,778,000.00 ✓	$9,798.13
Total dividends collected	$5085877075297.57M ✓	$28.9K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: LOBEF vs MRK ($10,000, DRIP)

Year	LOBEF Portfolio	LOBEF Income/yr	MRK Portfolio	MRK Income/yr	Gap
1← crossover	$396,800	$386,100.39	$11,206	$366.19	+$385.6K → LOBEF
2	$14,742,780	$14,318,203.95	$12,650	$502.35	+$14.73M → LOBEF
3	$512,952,973	$497,178,198.17	$14,407	$694.19	+$512.94M → LOBEF
4	$16,715,748,598	$16,166,888,916.48	$16,585	$967.82	+$16715.73M → LOBEF
5	$510,255,139,456	$492,369,288,456.53	$19,342	$1,363.89	+$510255.12M → LOBEF
6	$14,592,492,784,652	$14,046,519,785,434.00	$22,913	$1,947.19	+$14592492.76M → LOBEF
7	$391,042,310,644,499	$375,428,343,364,921.60	$27,662	$2,823.89	+$391042310.62M → LOBEF
8	$9,820,789,713,309,148	$9,402,374,440,919,534.00	$34,159	$4,173.35	+$9820789713.27M → LOBEF
9	$231,195,080,018,900,830	$220,686,835,025,660,030.00	$43,337	$6,308.80	+$231195080018.86M → LOBEF
10	$5,102,776,617,540,002,000	$4,855,397,881,919,778,000.00	$56,776	$9,798.13	+$5102776617539.95M → LOBEF

LOBEF vs MRK: Complete Analysis 2026

LOBEF — Stock

Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. It develops psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and post-traumatic stress disorder, as well as devices for the efficient application of medications. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.

Full LOBEF Calculator →

MRK — Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →

📬

Get this LOBEF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LOBEF vs SCHD LOBEF vs JEPI LOBEF vs O LOBEF vs KO LOBEF vs MAIN LOBEF vs JNJ LOBEF vs ABBV LOBEF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.